4-HO-MPMI
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 250672-65-2 |
| ATC code | ? |
| PubChem | CID 10466404 |
| Chemical data | |
| Formula | C14H17N2O |
| Mol. mass | 229.297 g/mol |
| SMILES | eMolecules & PubChem |
 (what is this?) (verify) |
4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine or lucigenol) is a tryptamine derivative that is a hallucinogenic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine derived hallucinogen DOI, and has two enantiomers, with only the (R)-enantiomer being active.[1]
The binding affinity for 5-HT2A receptor is 13 +/- 2 nM (Ki [125I]DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six to eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety.[2][unreliable source?]
[edit] See also
[edit] References
- ^ Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE (1999). "Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain". Journal of Medicinal Chemistry 42 (20): 4257–4263. doi:10.1021/jm990325u. PMID 10514296.
- ^ http://www.hipforums.com/newforums/showthread.php?t=315326
